Bli medlem
Bli medlem

Du är här

2016-11-01

Diamyd Medical AB: Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced
that production of a proprietary GABA drug has started. Concurrently,
the Scientific and Medical Advisory Board is expanded with two
leading experts in rheumatoid arthritis and type 2 diabetes,
Professor Daniel Furst, University of California, Los Angeles (UCLA)
and Associate Professor Michael Alvarsson, Clinic Director at the
Karolinska University Hospital.

Diamyd Medical has as previously reported broadened its operations to
include type 2 diabetes and rheumatoid arthritis with its own GABA
drug. Development of a GABA-drug product has now been launched in
collaboration with a supplier of GMP production and preclinical
studies to determine the dose and formulation start shortly.

To further strengthen its expertise in type 2 diabetes and rheumatoid
arthritis, Diamyd Medical has expanded its Scientific and Medical
Advisory Board with two new members, Professor Daniel Furst and
Associate Professor Michael Alvarsson.

Daniel Furst, Professor at the University of California, Los Angeles
(UCLA) and rheumatologist, has published over 800 articles and 15
books, including 430 scientific publications, in his field. Doctor
Furst's research include clinical pharmacology of anti-rheumatic
drugs and the pathophysiology and treatment of systemic sclerosis.

Michael Alvarsson is Senior Consultant Physician at the Department of
Endocrinology, Metabolism and Diabetes at Karolinska University
Hospital and Associate Professor at the Karolinska Institute, where
he conducts clinical diabetes research at the Department of Molecular
Medicine and Surgery. Doctor Alvarsson has long experience from
clinical studies in type 2 diabetes as principal investigator for
numerous multinational clinical trials.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other
serious inflammatory diseases through pharmaceutical development and
investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an
antigen-specific immunotherapy based on the exclusively licensed
GAD-molecule. Six clinical studies are ongoing with Diamyd®. GABA
constitutes alongside with the diabetes vaccine a key asset in Diamyd
Medical and the Company uses its GABA in-licensed technology to
develop a proprietary GABA drug product. Diamyd Medical is one of the
major shareholders in the stem cell company NextCell Pharma AB
(former Cellaviva AB). Diamyd Medical also has holdings in the
medtech company Companion Medical, Inc., San Diego, USA and in the
gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical's B-share is traded on Nasdaq Stockholm First North
under the ticker DMYD B. Remium Nordic AB is the Company's Certified
Adviser.

För ytterligare information, kontakta:
Ulf Hannelius, vd
Tel: +46 736 35 42 41.
E-post: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sverige. Tel: +46 8 661 00 26,
Fax: +46 8 661 63 68

E-post: info@diamyd.com Org. nr: 556242-3797 Hemsida: www.diamyd.com
Denna information är sådan information som Diamyd Medical är skyldigt
att offentliggöra enligt EU:s marknadsmissbruksförordning.
Informationen lämnades, genom ovanstående kontaktpersons försorg, för
offentliggörande den 1 november 2016 kl 08.30 CET

-----------------------------------------------------------
http://news.cision.com/diamyd-medical-ab/r/diamyd-medical-starts-produci...
http://mb.cision.com/Main/6746/2112868/583164.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.